CO2018000086A2 - Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona - Google Patents

Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Info

Publication number
CO2018000086A2
CO2018000086A2 CONC2018/0000086A CO2018000086A CO2018000086A2 CO 2018000086 A2 CO2018000086 A2 CO 2018000086A2 CO 2018000086 A CO2018000086 A CO 2018000086A CO 2018000086 A2 CO2018000086 A2 CO 2018000086A2
Authority
CO
Colombia
Prior art keywords
iodophenylamino
azetidin
methanone
difluoro
fluoro
Prior art date
Application number
CONC2018/0000086A
Other languages
English (en)
Inventor
Adrian St Clair Brown
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56411938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018000086(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CO2018000086A2 publication Critical patent/CO2018000086A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

RESUMEN La presente descripción se refiere a la sal de fumarato cristalina de (S)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona. La descripción también se refiere a composiciones farmacéuticas que comprenden la sal de fumarato cristalina de (S)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona. La descripción también se refiere a métodos para tratar cánceres que comprenden administrarle a un paciente que lo necesita la sal de fumarato cristalina de (S)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona.
CONC2018/0000086A 2015-06-30 2018-01-05 Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona CO2018000086A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562187009P 2015-06-30 2015-06-30
PCT/US2016/040444 WO2017004393A1 (en) 2015-06-30 2016-06-30 Crystalline fumarate salt of (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone

Publications (1)

Publication Number Publication Date
CO2018000086A2 true CO2018000086A2 (es) 2018-04-10

Family

ID=56411938

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0000086A CO2018000086A2 (es) 2015-06-30 2018-01-05 Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Country Status (24)

Country Link
US (3) US10590102B2 (es)
EP (1) EP3317264A1 (es)
JP (3) JP7338950B2 (es)
KR (1) KR102695324B1 (es)
CN (2) CN118290395A (es)
AR (1) AR105483A1 (es)
AU (2) AU2016288209B2 (es)
CA (1) CA2990222C (es)
CL (1) CL2017003475A1 (es)
CO (1) CO2018000086A2 (es)
CR (1) CR20180056A (es)
HK (1) HK1252433A1 (es)
IL (2) IL295052A (es)
MA (1) MA42301A (es)
MX (1) MX2017017037A (es)
MY (1) MY192545A (es)
PE (1) PE20180692A1 (es)
PH (1) PH12017502414A1 (es)
RU (2) RU2021132394A (es)
SG (1) SG10202105196YA (es)
TW (2) TWI710556B (es)
UA (1) UA124728C2 (es)
WO (1) WO2017004393A1 (es)
ZA (1) ZA201708760B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
EP3881833B1 (en) * 2015-06-30 2023-11-01 Genentech, Inc. Immediate-release tablets containing a drug and processes for forming the tablets
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
GB201717809D0 (en) * 2017-10-30 2017-12-13 Azad Pharmaceutical Ingredients Ag Process for the production of cobimetinib
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
WO2024111001A1 (en) * 2022-11-25 2024-05-30 Msn Laboratories Private Limited, R&D Center Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1802579T3 (da) 2004-10-20 2014-01-20 Merck Serono Sa Derivater af 3-arylaminopyridin
CA2609353C (en) 2005-05-23 2015-04-28 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
MX2015011713A (es) 2013-03-05 2016-05-09 Univ Tennessee Res Foundation Compuestos para el tratamiento de cancer.
WO2014152358A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
US20220056010A1 (en) 2022-02-24
US11254649B2 (en) 2022-02-22
PH12017502414A1 (en) 2018-06-25
AU2016288209A1 (en) 2018-02-08
MX2017017037A (es) 2018-04-30
KR102695324B1 (ko) 2024-08-13
RU2018103172A3 (es) 2019-10-31
RU2021132394A (ru) 2021-11-18
PE20180692A1 (es) 2018-04-23
JP7338950B2 (ja) 2023-09-05
MA42301A (fr) 2018-05-09
IL256423A (en) 2018-02-28
BR112017028516A2 (pt) 2018-08-28
IL256423B (en) 2022-09-01
CR20180056A (es) 2018-05-25
CA2990222C (en) 2023-09-26
JP2021035967A (ja) 2021-03-04
JP2018519318A (ja) 2018-07-19
IL295052A (en) 2022-09-01
TWI775187B (zh) 2022-08-21
AU2016288209B2 (en) 2020-10-22
WO2017004393A1 (en) 2017-01-05
RU2762181C2 (ru) 2021-12-16
US20180346442A1 (en) 2018-12-06
RU2018103172A (ru) 2019-07-31
UA124728C2 (uk) 2021-11-10
JP2023025000A (ja) 2023-02-21
TWI710556B (zh) 2020-11-21
CN118290395A (zh) 2024-07-05
EP3317264A1 (en) 2018-05-09
TW201718535A (zh) 2017-06-01
CA2990222A1 (en) 2017-01-05
ZA201708760B (en) 2022-06-29
CL2017003475A1 (es) 2018-07-13
AU2021200202B2 (en) 2022-09-08
HK1252433A1 (zh) 2019-05-24
SG10202105196YA (en) 2021-06-29
KR20180021775A (ko) 2018-03-05
TW202108568A (zh) 2021-03-01
AR105483A1 (es) 2017-10-11
US10590102B2 (en) 2020-03-17
MY192545A (en) 2022-08-26
CN107810183A (zh) 2018-03-16
AU2021200202A1 (en) 2021-03-18
US20200255398A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
CO2018000086A2 (es) Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
PH12018501226A1 (en) Methods for treating huntingtons disease
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12016501654A1 (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2016008968A (es) Compuestos organicos.
BR112017020180A2 (pt) derivados de aminohidrotiazina fundida em tetrahidrofurano que são úteis no tratamento da doença de alzheimer
BR112016029604A2 (pt) ?sais farmaceuticamente aceitáveis, forma cristalina, padrão cristalino, composições farmacêuticas, sais de glucamina, utilização de um sal e de uma composição farmacêutica, método para o tratamento do câncer e composto para a utilização?
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.
MX2018004532A (es) Combinacion de trazodona y gabapentina para el tratamiento de dolor.
EA201791398A1 (ru) Производные фумагиллола
AR097890A1 (es) Compuestos de urea
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.